Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norethindrone acetate for Nexplanon-associated bleeding
NCT04676061Phase 4Terminated
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of norethisterone acetate in breakthrough bleeding (2 arms), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Number of days of bleeding and spotting at 30 days. Started Feb 2021; status: terminated.
02
Drugs
norethisterone acetate
03
Conditions
breakthrough bleeding
Beyond the preview
Go deeper on NCT04676061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676061.